The below Parliamentary question was asked by Andrew Percy on 2016-01-26.
To ask the Secretary of State for Business, Innovation and Skills, whether the National Dementia Research Institute will conduct research into Parkinson’s dementia as part of its core work.
Joseph Johnson
I refer my hon Friend to the answer I gave to Question UIN 18130
“
The below Parliamentary question was asked by Andrew Percy on 2016-02-24.
To ask the Secretary of State for Health, what steps he has taken to support the British Heart Foundations’ Wear It Beat It campaign.
Jane Ellison
We congratulate the British Heart Foundation (BHF) on its Wear It Beat It campaign, which aims to raise funds for research into heart disease.
Heart disease is a vital area of research. The Department’s National Institute for Health Research (NIHR) funds a wide range of research relating to these conditions, spending £49 million on cardiovascular disease research in 2014/15. The NIHR works in partnership with the BHF and other medical research charities.
The below Parliamentary question was asked by Andrew Percy on 2016-02-24.
To ask the Secretary of State for Justice, what assessment he has made of the effects on children and families of the parental orders procedure following surrogacy arrangements.
Caroline Dinenage
The Government has made no such assessment. Parental orders provide a mechanism to enable a couple who have entered into a surrogacy arrangement to become that child’s legal parents. There is no obligation to obtain a parental order but a couple who commission a surrogacy arrangement are advised and encouraged to do so in order to achieve a recognisable transfer of parenthood in the UK. In deciding whether to exercise its discretion and award a Parental order, the court has regard to all the facts of the case and the overriding importance of the welfare of the child throughout their life.
The below Parliamentary question was asked by Andrew Percy on 2016-03-07.
To ask the Secretary of State for Communities and Local Government, if he will take steps to provide more information to people potentially affected by floods to enable them to access grant schemes from local authorities.
James Wharton
Our immediate priority remains doing everything we can to help local communities repair and recover from floods. This means ensuring all those affected can benefit from the £200 million grant schemes offered by the Government and know that they can do so.
We have provided information on the Gov.uk website and have worked with local authorities to ensure their websites are up to date. We have also developed a simple fact sheet for individual property owners explaining the Property Level Resilience grant scheme and how to apply for it.
We are in regular contact with local areas and are continuing to look at ways to help support their residents and businesses take full advantage of the grants available.
The below Parliamentary question was asked by Andrew Percy on 2016-03-24.
To ask the Secretary of State for Health, whether his Department plans to use the inflammatory bowel disease (IBD) registry to get an accurate number of people living with IBD.
Jane Ellison
The IBD (inflammatory bowel disease) Registry provides a United Kingdom-wide repository of anonymised IBD adult and paediatric patient data for prospective audit and research purposes. Patients must consent for their data to be added to the registry. The Healthcare Quality Improvement Partnership (HQIP) has allocated transitional funding this year to incorporate IBD audit data collection into the IBD Registry, providing an enhanced system for data capture and quality improvement that will be available to every hospital in the UK. This will allow the entry of data locally and support service improvement. Initially the focus will be for IBD patients receiving biologic treatments, but the system will address other key aspects of IBD care in the future.
The second step of data collection will be to focus on new patients with IBD to begin to understand the incidence of IBD in the UK. This picture will build up over a number of years and be dependent on the engagement of clinicians.
No specific assessment of the potential effects on healthcare due to the introduction of a registry of patients with IBD in England has been made. However, the data provided through the register can support National Health Service services in areas such as the assessment of local IBD populations as well as in measuring incidence and outcomes with services in other parts of the UK.
Although there is no direct Department funding, HQIP have given £290,000 for a year’s transition funding to join the audit data with the registry.
The National Institute for Health and Care Excellence (NICE) recommends faecal calprotectin testing as an option to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome.
The NICE IBD Quality Standard states that general practitioners (GP) and GP practices should ensure that testing is offered and clinical commissioning groups should ensure the diagnostic services are in place to support this.
The below Parliamentary question was asked by Andrew Percy on 2016-04-25.
To ask the Secretary of State for Culture, Media and Sport, if he will discuss with the Information Commissioner’s Office reasons to refer consumer complaints to equivalent bodies overseas in addressing nuisance telephone calls from abroad.
Mr Edward Vaizey
This Government recently made an amendment to the Privacy and Electronic Communications Regulations 2003 (PECR), requiring direct marketing companies registered in the UK and those making calls on behalf of UK companies from outside the UK, to display Calling Line Identification. This measure will make it easier for the ICO to investigate and take enforcement action against callers who persistently and deliberately flout the rules.
In addtion, both the Information Commissioner’s Office (ICO) and Ofcom engage with the Do Not Call Forum of the London Action Plan, which includes overseas regulators with responsibility for tackling nuisance calls. The ICO is joint secretariat and works with other members, including the US Federal Trade Commission (FTC) and the Canadian Radio-television and Telecommunications Commission, to target organisations, share investigation methods and drive forward coordinated actions. The group are drafting an operational plan to strengthen cooperation at international level
The below Parliamentary question was asked by Andrew Percy on 2016-05-23.
To ask the Secretary of State for the Home Department, how many people have been convicted of offences of online abuse on (a) Facebook and (b) Twitter under the Communications Act 2003 since 2010.
Karen Bradley
The Home Office do not hold the information requested. The Ministry of Justice hold data on the number of offenders found guilty at all courts in England and Wales.
The below Parliamentary question was asked by Andrew Percy on 2015-10-26.
To ask the Secretary of State for Health, what estimate his Department has made of the number of people with both ulcerative colitis and Crohn’s disease who have benefitted from the use of vedolizumab as a treatment option since February 2015; and what the cost of this treatment has been in that period.
George Freeman
Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.
Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.
In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.
In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.
NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance Crohn’s Disease Management in Adults, Children and Young People in October 2012, and Ulcerative Colitis Management in Adults, Children and Young People , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.
The below Parliamentary question was asked by Andrew Percy on 2015-10-26.
To ask the Secretary of State for Health, what recent assessment his Department has made of the effectiveness of vedolizumab as a treatment for Crohn’s disease.
George Freeman
Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.
Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.
In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.
In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.
NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance Crohn’s Disease Management in Adults, Children and Young People in October 2012, and Ulcerative Colitis Management in Adults, Children and Young People , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.
The below Parliamentary question was asked by Andrew Percy on 2015-10-27.
To ask the Secretary of State for Health, what assessment he has made of the time taken to decide on patient access scheme applications for drugs through the Cancer Drugs Fund.
George Freeman
Within the framework set out in the 2014 Pharmaceutical Price Regulation Scheme, a Patient Access Scheme (PAS) can be proposed by a pharmaceutical company and agreed by the Department to improve the cost-effectiveness of a medicine as part of a National Institute for Health and Care Excellence (NICE) technology appraisal.
A PAS proposal can only be submitted for a medicine that is available through the Cancer Drugs Fund if that product is also scheduled for appraisal or review by NICE and no assessment has been of the time taken to consider any such PAS proposals.